Fig. 2

Surface-TREM2 level on M-MDSCs from DLBCL patients. A Clinical characteristics (age, sex, IPI score, and Ann Arbor stage), representative coronal and axial view of PET image, and histogram of TREM2 level on PB M-MDSCs in two DLBCL patients. B Normalized MFI changes of surface TREM2 on PB M-MDSCs being subcategorized according to IPI risk scores; each line in the upper panel representing a pair of patient samples and the healthy control; each dot in the lower panel being calculated as follows: (patient’s TREM2 MFI—healthy control’s TREM2 MFI)/(healthy control’s TREM2 MFI) × 100%. Normalized MFI changes of surface TREM2 on PB M-MDSCs being subcategorized by C age, D sex, E bulky mass, F bone marrow involvement, G cell of origin, H double-expressor lymphoma, I absolute count of CD4⁺ T cells in PB, J absolute count of CD8⁺ T cells in PB, or K percentage of circulating M-MDSCs among PB CD45.⁺ cells. BM, bone marrow; DEL, double-expressor lymphoma; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B cell; HC, healthy control; IPI, international prognostic index; M-MDSCs, monocytic myeloid-derived suppressor cells; MFI, mean fluorescence intensity; PB, peripheral blood; PET, positron emission tomography; TREM2, triggering receptors expressed on myeloid cells 2